bioRxivImmunologyPreprint
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
J. E. Bowen, K. R. Sprouse, A. C. Walls, I. G. Mazzitelli, J. K. Logue, N. M. Franko, K. Ahmed, A. Shariq, E. Cameroni, A. Gori, A. Bori, C. M. Posavad, J. M. Dan, Z. Zhang, D. Weiskopf, A. Sette, S. Crotty, N. Talat Iqbal, D. Corti, J. Geffner, R. Grifantini, H. Y. Chu, D. Veesler
Abstract
The SARS-CoV-2 Omicron variant of concern comprises three sublineages designated BA.1, BA.2, and BA.3, with BA.2 steadily replacing the globally dominant BA.1. We show that the large number of BA.1 and BA.2 spike mutations severely dampen plasma neutralizing activity elicited by infection or seven clinical vaccines, with cross-neutralization of BA.2 being consistently more potent than that of BA.1, independent of the vaccine platform and number of doses. Although mRNA vaccines induced the greatest magnitude of Omicron BA.1 and BA.2 plasma neutralizing activity, administration of a booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1 and BA.2 across all vaccines evaluated. Our data suggest that although BA.1 and BA.2 evade polyclonal neutralizing antibody responses, current vaccine boosting regimens may provide sufficient protection against Omicron-induced disease.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1
M. E. Davis-Gardner, L. Lai, … M. S. Suthar·bioRxiv·Oct 31, 2022
- Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
S. M. Scheaffer, D. Lee, … M. S. Diamond·bioRxiv·Sep 12, 2022
- Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
- Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
- mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
V.-V. Edara, K. E. Manning, … M. S. Suthar·bioRxiv·Dec 20, 2021
- Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages